EUVIMEDEUVIMED entdecken
Crossref

Molecular characterization of 13 patients with PIK3CA ‐related overgrowth spectrum using a targeted deep sequencing approach

Leanne de Kock iD, Alexanne Cuillerier iD, Meredith Gillespie, Madeline Couse, Taila Hartley iD, Wendy Mears, Francois P Bernier, Albert E Chudley, Patrick Frosk iD, Sarah M Nikkel, A Micheil Innes iD, Julie Lauzon und 11 weitere

American Journal of Medical Genetics Part A · 2024

DOI: 10.1002/ajmg.a.63466 ↗

Kurz gefasst

Fachartikel in der Zeitschrift American Journal of Medical Genetics Part A, 2024. Verfasst von Leanne de Kock und 22 weiteren Autor:innen. Beteiligte Einrichtung: Children's Hospital of Eastern Ontario Research Institute, Ottawa, Ontario, Canada. Hauptthemen laut MEDLINE: Musculoskeletal Abnormalities, Megalencephaly, Vascular Malformations, Abnormalities, Multiple. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 33 Literaturangaben. Gefördert von: CIHR, Canadian Institutes of Health Research, Genome Alberta.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Activating variants in the PIK3CA gene cause a heterogeneous spectrum of disorders that involve congenital or early‐onset segmental/focal overgrowth, now referred to as PIK3CA ‐related overgrowth spectrum (PROS). Historically, the clinical diagnoses of patients with PROS included a range of distinct syndromes, including CLOVES syndrome, dysplastic megalencephaly, hemimegalencephaly, focal cortical dysplasia, Klippel–Trenaunay syndrome, CLAPO syndrome, fibroadipose hyperplasia or overgrowth, hemihyperplasia multiple lipomatosis, and megalencephaly capillary malformation‐polymicrogyria (MCAP) syndrome. MCAP is a sporadic overgrowth disorder that exhibits core features of progressive megalencephaly, vascular malformations, distal limb malformations, cortical brain malformations, and connective tissue dysplasia. In 2012, our research group contributed to the identification of predominantly mosaic, gain‐of‐function variants in PIK3CA as an underlying genetic cause of the syndrome. Mosaic variants are technically more difficult to detect and require implementation of more sensitive sequencing technologies and less stringent variant calling algorithms. In this study, we demonstrated the utility of deep sequencing using the Illumina TruSight Oncology 500 (TSO500) sequencing panel in identifying variants with low allele fractions in a series of patients with PROS and suspected mosaicism: pathogenic, mosaic PIK3CA variants were identified in all 13 individuals, including 6 positive controls. This study highlights the importance of screening for low‐level mosaic variants in PROS patients. The use of targeted panels with deep sequencing in clinical genetic testing laboratories would improve diagnostic yield and accuracy within this patient population.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Musculoskeletal AbnormalitiesMegalencephalyVascular MalformationsAbnormalities, MultipleSkin Diseases, VascularHumansMutationClass I Phosphatidylinositol 3-KinasesHigh-Throughput Nucleotide SequencingTelangiectasis

Stichwörter der Autor:innen

PIK3CAPROSmosaicismovergrowth syndromerare genetic disease

Substanzen

Class I Phosphatidylinositol 3-KinasesPIK3CA protein, human

Autor:innen und Institutionen

  • Children's Hospital of Eastern Ontario Research Institute, Ottawa, Ontario, Canada.
  • Department of Pediatrics, University of Ottawa, Ottawa, Ontario, Canada.
  • The Centre for Computational Medicine, the Hospital for Sick Children (SickKids) Research Institute, Toronto, Ontario, Canada.
  • Alberta Children's Hospital Research Institute, University of Calgary, Calgary, Alberta, Canada.
  • Department of Medical Genetics, Alberta Children's Hospital, Calgary, Alberta, Canada.
  • Department of Pediatrics and Child Health, Max Rady College of Medicine, Rady Faculty of Health Sciences, University of Manitoba, Winnipeg, Manitoba, Canada.

ORCID-Profile: Leanne de Kock, Alexanne Cuillerier, Taila Hartley, Patrick Frosk, A Micheil Innes, Andrea Guerin, Rosanna Weksberg, Cheryl Cytrynbaum, Kym M Boycott

Förderung

  • CIHR
  • Canadian Institutes of Health Research
  • Genome Alberta
  • Genome British Columbia
  • Genome Canada
  • Génome Québec
  • Ontario Genomics Institute
  • Ontario Research Foundation

Zitieren

APA

de Kock, L., Cuillerier, A., Gillespie, M., Couse, M., Hartley, T., Mears, W., Bernier, F. P., Chudley, A. E., Frosk, P., Nikkel, S. M., Innes, A. M., Lauzon, J., Thomas, M., Guerin, A., Armour, C. M., Weksberg, R., Scott, J. N., Watkins, D., Harvey, S., …, & Boycott, K. M. (2024). Molecular characterization of 13 patients with PIK3CA ‐related overgrowth spectrum using a targeted deep sequencing approach. American Journal of Medical Genetics Part A. https://doi.org/10.1002/ajmg.a.63466

Vancouver

de Kock L, Cuillerier A, Gillespie M, Couse M, Hartley T, Mears W, et al. Molecular characterization of 13 patients with PIK3CA ‐related overgrowth spectrum using a targeted deep sequencing approach. American Journal of Medical Genetics Part A. 2024. doi:10.1002/ajmg.a.63466

BibTeX
@article{deKock2024,
  author = {de Kock, Leanne and Cuillerier, Alexanne and Gillespie, Meredith and Couse, Madeline and Hartley, Taila and Mears, Wendy and Bernier, Francois P and Chudley, Albert E and Frosk, Patrick and Nikkel, Sarah M and Innes, A Micheil and Lauzon, Julie and Thomas, Maryann and Guerin, Andrea and Armour, Christine M and Weksberg, Rosanna and Scott, James N and Watkins, Debra and Harvey, Shirley and Cytrynbaum, Cheryl and Care4Rare Canada Consortium, Care4Rare Canada Consortium and Kernohan, Kristin D and Boycott, Kym M},
  title = {Molecular characterization of 13 patients with PIK3CA ‐related overgrowth spectrum using a targeted deep sequencing approach},
  journal = {American Journal of Medical Genetics Part A},
  year = {2024},
  doi = {10.1002/ajmg.a.63466}
}
Kostenlos starten →